Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):451–453. doi: 10.1038/bjc.1991.104

Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.

C Fabris 1, A Malesci 1, D Basso 1, C Bonato 1, G Del Favero 1, M Tacconi 1, T Meggiato 1, P Fogar 1, M P Panozzo 1, C Ferrara 1, et al.
PMCID: PMC1971859  PMID: 2003987

Abstract

The usefulness of serum DU-PAN-2 in diagnosing pancreatic cancer and in distinguishing between this cancer and other benign and malignant diseases, and to assess the role of liver dysfunction in altering the serum levels of this marker were investigated. DU-PAN-2 was measured in the sera of 31 patients with pancreatic cancer, 32 with chronic pancreatitis, 20 with benign and 21 with malignant extra-pancreatic diseases. DU-PAN-2 was found to be above 300 U ml-1 in 21/31 patients with pancreatic cancer (sensitivity 68%). Only 3/32 patients with chronic pancreatitis had abnormal values. A substantial number of patients with both benign and malignant extra-pancreatic diseases had an elevated serum DU-PAN-2 (9/20 and 15/21, respectively). Correlations were found between DU-PAN-2 and (1) total bilirubin, (2) alanine-amino-transferase and (3) alkaline phosphatase. Of the patients with high DU-PAN-2 values, jaundice was found in: 2/3 with chronic pancreatitis, 9/10 with benign and 12/14 with malignant extra-pancreatic diseases. In conclusion, the serum DU-PAN-2 test for pancreatic malignancy is not completely satisfactory, because it is not sensitive enough. While the test for chronic pancreatitis has an acceptable specificity, the assay cannot distinguish between pancreatic cancer and other extra-pancreatic diseases, mainly of the liver and biliary tract. Liver dysfunction as well as jaundice seem to considerable affect the levels of this marker, as reported elsewhere for CA 19-9.

Full text

PDF
451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basso D., Fabris C., Del Favero G., Angonese C., Meggiato T., Infantino A., Plebani M., Piccoli A., Leandro G., Burlina A. Serum carcinoembryonic antigen in the differential diagnosis of pancreatic cancer: influence of tumour spread, liver impairment, and age. Dis Markers. 1988 Jul-Sep;6(3):203–207. [PubMed] [Google Scholar]
  2. Bull T. E., Andrasko J., Chiancone E., Forsen S. Pulsed nuclear magnetic resonance studies on 23 Na, 7 Li and 35 Cl binding to human oxy- and carbon monoxyhaemoglobin. J Mol Biol. 1973 Jan 10;73(2):251–259. doi: 10.1016/0022-2836(73)90327-6. [DOI] [PubMed] [Google Scholar]
  3. Cubilla A., Fitzgerald P. J. Pancreas cancer. I. Duct adenocarcinoma. A clinical-pathologic study of 380 patients. Pathol Annu. 1978;13(Pt 1):241–289. [PubMed] [Google Scholar]
  4. Del Favero G., Fabris C., Panucci A., Basso D., Plebani M., Baccaglini U., Leandro G., Burlina A., Naccarato R. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Bull Cancer. 1986;73(3):251–255. [PubMed] [Google Scholar]
  5. Fabris C., Del Favero G., Basso D., Piccoli A., Meggiato T., Angonese C., Plebani M., Leandro G., Burlina A., Naccarato R. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Am J Gastroenterol. 1988 May;83(5):549–553. [PubMed] [Google Scholar]
  6. Farini R., Fabris C., Bonvicini P., Piccoli A., del Favero G., Venturini R., Panucci A., Naccarato R. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol. 1985 Apr;21(4):429–432. doi: 10.1016/0277-5379(85)90032-x. [DOI] [PubMed] [Google Scholar]
  7. Haviland A. E., Borowitz M. J., Killenberg P. G., Lan M. S., Metzgar R. S. Detection of an oncofetal antigen (DU-PAN-2) in sera of patients with non-malignant hepatobiliary diseases and hepatomas. Int J Cancer. 1988 Jun 15;41(6):789–793. doi: 10.1002/ijc.2910410602. [DOI] [PubMed] [Google Scholar]
  8. Lan M. S., Finn O. J., Fernsten P. D., Metzgar R. S. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res. 1985 Jan;45(1):305–310. [PubMed] [Google Scholar]
  9. Mahvi D. M., Seigler H. F., Meyers W. C., Kalthoff H., Schmiegel W. H., Metzgar R. S. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas. 1988;3(4):488–493. doi: 10.1097/00006676-198808000-00020. [DOI] [PubMed] [Google Scholar]
  10. Metzgar R. S., Rodriguez N., Finn O. J., Lan M. S., Daasch V. N., Fernsten P. D., Meyers W. C., Sindelar W. F., Sandler R. S., Seigler H. F. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A. 1984 Aug;81(16):5242–5246. doi: 10.1073/pnas.81.16.5242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pleskow D. K., Berger H. J., Gyves J., Allen E., McLean A., Podolsky D. K. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989 May 1;110(9):704–709. doi: 10.7326/0003-4819-110-9-704. [DOI] [PubMed] [Google Scholar]
  12. Sakamoto K., Haga Y., Yoshimura R., Egami H., Yokoyama Y., Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut. 1987 Mar;28(3):323–329. doi: 10.1136/gut.28.3.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sawabu N., Toya D., Takemori Y., Hattori N., Fukui M. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Int J Cancer. 1986 May 15;37(5):693–696. doi: 10.1002/ijc.2910370509. [DOI] [PubMed] [Google Scholar]
  14. Steinberg W. M., Gelfand R., Anderson K. K., Glenn J., Kurtzman S. H., Sindelar W. F., Toskes P. P. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986 Feb;90(2):343–349. doi: 10.1016/0016-5085(86)90930-3. [DOI] [PubMed] [Google Scholar]
  15. Suzuki Y., Ichihara T., Nakao A., Sakamoto J., Takagi H., Nagura H. High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells. Hepatogastroenterology. 1988 Jun;35(3):128–135. [PubMed] [Google Scholar]
  16. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES